Novartis has made a $200 million upfront investment to license Arrowhead Pharmaceuticals’ preclinical siRNA drug ARO-SNCA, targeting alpha-synuclein for Parkinson’s disease and other synucleinopathies. The collaboration, potentially worth over $2 billion in milestones, leverages Arrowhead’s TRiM delivery platform enabling subcutaneous RNAi administration crossing the blood-brain barrier. Arrowhead retains preclinical development and regulatory responsibilities, while Novartis leads later clinical and commercial efforts. This deal marks Novartis’ continued commitment to novel neurodegenerative disease therapies using RNA interference technologies, an area witnessing renewed interest despite prior clinical setbacks in Parkinson’s drug development.